论文部分内容阅读
人体肠道各种双糖酶均可因先天性或继发性缺乏而引起相应的双糖消化吸收障碍。其中乳糖酶缺乏在东方人种内普遍存在。所引起的不良影响,对处于哺乳期的婴幼儿尤为严重。用外源性的双糖酶口服以辅助双糖消化吸收是一个较好的治疗方法。但是,由于微生物来源的双糖酶在消化道易被胃酸和胃肠道蛋白酶破坏,国外在临床试验中曾采取高剂量酶制剂口服的方法,以保证有足够的双糖酶残留量进入小肠发挥作用。此法成本高且疗效不稳定。本文报道双糖酶肠溶微囊的研制。体外实验证实,本制剂能使双糖酶在人体小肠内释放而避免被胃液破坏。有希望用于双糖吸收障碍症的临床治疗。
Various disaccharidases of the human intestine may be due to congenital or secondary deficiency caused by the corresponding disaccharide digestion and absorption disorders. Among them, lactase deficiency is common in oriental species. The adverse effects caused are particularly serious for infants and toddlers who are breast-feeding. Oral use of exogenous disaccharidase to aid digestion and absorption of sugar is a better treatment. However, due to microbial disaccharidase in the digestive tract susceptible to gastric acid and gastrointestinal protease damage, foreign clinical trials have taken high-dose enzyme preparation of oral methods to ensure that there is enough disaccharidase residues into the small intestine play effect. This method is costly and the efficacy is not stable. This article reports the development of disaccharidase enteric-coated microcapsules. In vitro experiments confirmed that the preparation can make disaccharidase release in the human small intestine to avoid damage to the gastric juice. There is hope for the clinical treatment of disaccharide dysfunction.